INTRODUCTION AND OBJECTIVES: Novel antibodies against immune checkpoint proteins, which led to unleash anti-tumor T cell responses, results in durable long-lasting responses but only in a fraction of patients. RFA of tumors can enhance systemic antitumor immunity through a series of mechanisms. Nevertheless, antitumor immunity induced by RFA is mostly weak and not sufficient enough to eradicate metastatic tumors completely or prevent disease progression durably. We hypothesized that these two different treatment strategies could act synergistically. The purpose of this study is to evaluate whether the combination of RFA and anti-PD-1 antibody could result in both primary tumor control and prevention of lung metastasis in a murine model bearing renal adenocarcinoma.
INTRODUCTION AND OBJECTIVES: Novel antibodies against immune checkpoint proteins, which led to unleash anti-tumor T cell responses, results in durable long-lasting responses but only in a fraction of patients. RFA of tumors can enhance systemic antitumor immunity through a series of mechanisms. Nevertheless, antitumor immunity induced by RFA is mostly weak and not sufficient enough to eradicate metastatic tumors completely or prevent disease progression durably. We hypothesized that these two different treatment strategies could act synergistically. The purpose of this study is to evaluate whether the combination of RFA and anti-PD-1 antibody could result in both primary tumor control and prevention of lung metastasis in a murine model bearing renal adenocarcinoma.
METHODS: Balb/c mice were injected with Renca cells into their left kidney to establish the orthotopical model of renal cancer. One week later, the mice were injected intravenously with Renca cells, which afterwards would spread into various organs particularly into the lung. Then, the mice were treated with IgG alone, anti-PD-1 monoclonal antibodies (mAbs), surgical resection/RFA of the kidney tumor, or surgical resection / RFA + anti-PD-1. anti-PD-1 mAbs were administered by intravenous injection (i.v) every other day for three times. The antitumor effect of the treatment was evaluated by counting the numbers of the tumors in the lung, weighing the lungs and observing the survival time, and the immunological responses were assessed using peripheral blood immune parameters and analyzing the infiltration of CD+4 or CD+8 T cells into the tumors.
RESULTS: Treatment of mice bearing kidney tumors with RFA and anti-PD-1 mAbs resulted in significantly greater growth suppression of primary kidney tumors and prolonged survival compared with mice treated with the other modalities. ELISA analysis showed that mice treated with RFA and i.v anti-PD-1 mAbs had higher level of IFN-g, TNF-a in the peripheral blood after treatment compared with the other groups. In the combination therapy group, growth of lung metastases was prevented with fewer numbers of lung metastases and lighter weight of lung. The combined therapy of RFA and anti-PD-1 antibodies significantly increased T-cell infiltration, especially the effector T cells, which upregulated the effector T cells to regulatory T cells ratio.
CONCLUSIONS: The combination of RFA and anti-PD-1 mAbs resulted in stronger antitumor immunity and prolonged survival in this preeclinical model of advanced RCC. 
MP16-19 NEOADJUVANT AND ADJUVANT CHEMOTHERAPY FOLLOWING NEPHROURETERECTOMY: CHANGES IN UTILIZATION AND OUTCOMES
Adrien Bernstein*, Ron Golan, Brian Dinerman, Michael Cosiano, Khushabu Kasabwala, Jim C. Hu, NEW YORK, NY INTRODUCTION AND OBJECTIVES: Nephroureterectomy is the mainstay therapy for high-grade upper tract urothelial carcinoma (UTUC). As the survival remains poor for high-grade UTUC following nephroureterectomy, a number of ongoing studies are investigating the utility of neoadjuvant chemotherapy (NAC) in this disease. While awaiting these results, our objective is to examine the utilization of NAC, impact on outcomes following surgery and overall survival in a national hospital-based analysis.
METHODS: We identified subjects diagnosed with urothelial carcinoma of the kidney or ureter from the National Cancer Database during 2004-2014, who underwent nephroureterectomy. These subjects were then stratified on the basis of receipt of NAC, and univariable and multivariable analysis was performed to identify patient and provider factors associated with use of NAC. Thirty-day mortality and readmission were assessed by chi-squared analysis. Adjusted Coxregression was used to evaluate overall survival. RESULTS: We identified 26,309 subjects who underwent nephroureterectomy for UTUC, and 421 (1.6%) received NAC. Median follow-up was 33 months (interquartile range 14-62). Utilization of NAC significantly increased over the study period (OR¼1.3 year over year, p<0.001). Younger patients (OR¼0.97 per year, p<0.001) and those with metastatic disease (lymph node OR¼2.0 and metastasis positive OR¼1.6, p<0.001) were more likely to receive NAC in their treatment regimens. NAC was more likely to be given at academic centers (OR ¼3.1 p<0.001); however, hospital UTUC volume was not associated with NAC use. Patient demographics such as race, income, and level of education were not associated NAC utilization. NAC was associated with better perioperative outcomes (30-day mortality 2.2% vs. 1.6%, p¼0.7 and 30-day readmission 3.9% vs. 3.1%, p¼0.02). Hazard ratios adjusting for age, pathologic stage, lymph node and metastasis status demonstrated that NAC was associated with survival [HR 0.82 (95% CI0.69-0.98) p¼0.029].
CONCLUSIONS: In our observational, hospital-based study, NAC is associated with improved survival without adversely affecting perioperative outcomes in those with high grade UTUC. Although use is increasing over time and greater at academic medical centers, it remains low overall. Prospective studies are needed to confirm these findings and identify optimal characteristics associated with improved outcomes. ST engenders concern that CN may shorten life or delay therapy. Thus, in all the best prognostic candidates, initial ST as a 00 litmus 00 test may be advocated prior to CN. We evaluated use of CN after initial ST, hypothesizing receipt of deferred CN to be associated with increased survival time, markers of increased performance status, less rapid disease and socioeconomic status.
METHODS: The National Cancer Database was screened for adult patients with biopsy-proven mRCC treated with initial systemic therapy between 2006-2013. Covariates included demographic, oncologic, hospital-level and geographic variables. Unadjusted and multivariable logistic regression was performed, identifying factors associated with CN after initial ST.
RESULTS: Of 14,651 patients treated with initial ST for mRCC, 709 (4.8%, median OS 19 months, IQR 9-35) underwent delayed CN compared with 13,942 (95.2%, median OS 5 months, IQR 2-13) treated with ST alone. On multivariable analysis, survival 3 months was highly associated with receipt of CN (OR 10.6, 95% CI 5.5, 20.5) . However, of 9,796 surviving 3 months, only 689 (7%) underwent CN. Factors associated with lower odds of CN included older age, greater comorbidity, higher clinical stage (T and N), and unfavorable metastatic sites (i.e., brain, bone, liver) with all p<0.001. Educational attainment was associated with receipt of CN, but hospital characteristics and travel burden were not. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e187
